New York State Common Retirement Fund Increases Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)

New York State Common Retirement Fund boosted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 12.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,969 shares of the company’s stock after purchasing an additional 16,249 shares during the period. New York State Common Retirement Fund owned about 0.16% of Myriad Genetics worth $2,029,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of MYGN. Creative Planning increased its stake in Myriad Genetics by 9.8% in the 3rd quarter. Creative Planning now owns 9,949 shares of the company’s stock worth $273,000 after purchasing an additional 892 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after buying an additional 583 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Myriad Genetics by 182.9% during the third quarter. Nisa Investment Advisors LLC now owns 11,417 shares of the company’s stock valued at $313,000 after buying an additional 7,381 shares during the period. New York State Teachers Retirement System increased its stake in shares of Myriad Genetics by 4.4% during the third quarter. New York State Teachers Retirement System now owns 73,900 shares of the company’s stock valued at $2,024,000 after buying an additional 3,102 shares during the period. Finally, Atria Investments Inc increased its stake in shares of Myriad Genetics by 5.4% during the third quarter. Atria Investments Inc now owns 11,414 shares of the company’s stock valued at $313,000 after buying an additional 581 shares during the period. 99.02% of the stock is owned by hedge funds and other institutional investors.

Myriad Genetics Trading Down 3.0 %

Myriad Genetics stock opened at $10.73 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The business’s fifty day simple moving average is $13.28 and its two-hundred day simple moving average is $18.97. Myriad Genetics, Inc. has a 12 month low of $9.76 and a 12 month high of $29.30. The company has a market capitalization of $976.81 million, a price-to-earnings ratio of -8.25 and a beta of 1.88.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. During the same period last year, the firm posted ($0.12) earnings per share. As a group, equities analysts predict that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Stephens reissued an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a research note on Thursday, January 16th. Bank of America reduced their target price on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research note on Friday, December 13th. The Goldman Sachs Group reduced their target price on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Morgan Stanley reduced their target price on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, November 18th. Finally, UBS Group reduced their target price on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 25th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $22.14.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.